The arginine methyltransferase PRMT5 promotes mucosal defense in the intestine
© 2023 Hernandez et al..
PRMT5 is a type II arginine methyltransferase abundantly expressed in the colonic epithelium. It is up-regulated in inflammatory bowel disease and colorectal cancer. However, its role in mucosal defense against enteric infection has not been studied. Here, we report that Prmt5 in the murine colon is up-regulated in response to Citrobacter rodentium infection. Pathogen clearance in mice with haploinsufficient expression of Prmt5 is significantly delayed compared with wildtype littermate controls. Transcriptomic analyses further reveal that PRMT5 regulates the expression of canonical crypt goblet cell genes involved in mucus production, assembly, and anti-microbial responses via methyltransferase activity-dependent and -independent mechanisms. Together, these findings uncover PRMT5 as a novel regulator of mucosal defense and a potential therapeutic target for treating intestinal diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Life science alliance - 6(2023), 11 vom: 07. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hernandez, Juan E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.09.2023 Date Revised 12.03.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.26508/lsa.202302026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361643748 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361643748 | ||
| 003 | DE-627 | ||
| 005 | 20240312233211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26508/lsa.202302026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM361643748 | ||
| 035 | |a (NLM)37666668 | ||
| 035 | |a (PII)e202302026 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hernandez, Juan E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The arginine methyltransferase PRMT5 promotes mucosal defense in the intestine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Hernandez et al. | ||
| 520 | |a PRMT5 is a type II arginine methyltransferase abundantly expressed in the colonic epithelium. It is up-regulated in inflammatory bowel disease and colorectal cancer. However, its role in mucosal defense against enteric infection has not been studied. Here, we report that Prmt5 in the murine colon is up-regulated in response to Citrobacter rodentium infection. Pathogen clearance in mice with haploinsufficient expression of Prmt5 is significantly delayed compared with wildtype littermate controls. Transcriptomic analyses further reveal that PRMT5 regulates the expression of canonical crypt goblet cell genes involved in mucus production, assembly, and anti-microbial responses via methyltransferase activity-dependent and -independent mechanisms. Together, these findings uncover PRMT5 as a novel regulator of mucosal defense and a potential therapeutic target for treating intestinal diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a PRMT2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a Protein-Arginine N-Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.319 |2 NLM | |
| 700 | 1 | |a Llorente, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Shengyun |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Kiana T |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Saptarshi |e verfasserin |4 aut | |
| 700 | 1 | |a Steele, Scarlet |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Zihui |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Ching-Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Zuniga, Elina I |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Pradipta |e verfasserin |4 aut | |
| 700 | 1 | |a Schnabl, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wendy Jia Men |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life science alliance |d 2018 |g 6(2023), 11 vom: 07. Nov. |w (DE-627)NLM286067536 |x 2575-1077 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:11 |g day:07 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26508/lsa.202302026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 11 |b 07 |c 11 | ||